• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    MIMEDX to Sponsor Leading Advanced Wound Care Conferences

    4/2/26 9:15:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MDXG alert in real time by email

    Multispecialty Focus with Industry Leadership Aimed at Improving Patient Outcomes

    Company Will Feature Recent Additions to Its Advanced Wound Care Portfolio

    MARIETTA, Ga., April 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced its participation in two leading wound care conferences: the Symposium on Advanced Wound Care ("SAWC") Spring 2026 and MedStar Georgetown University Hospital's Diabetic Limb Salvage ("DLS") Conference.

    Through scientific presentations, clinician education, and exhibit presence, MIMEDX will highlight its growing body of clinical evidence and expanding portfolio of solutions designed to support clinicians in managing complex wounds.

    "Clinicians are facing increasingly complex patients and rising expectations for outcomes, making access to both strong clinical evidence and a broad set of treatment options more important than ever," said John Harper, Ph.D., MIMEDX Chief Scientific Officer and SVP, R&D and Medical Affairs. "Our presence at SAWC and DLS reflects our continued commitment to advancing the science of wound care and supporting clinicians with solutions grounded in evidence, education, and real-world application."

    SAWC Spring 2026

    April 8–12 | Charlotte, NC | Booth 809

    MIMEDX will feature its portfolio of advanced wound care technologies and present new scientific data through a sponsored symposium and multiple accepted poster presentations.

    Lunch Symposium:

    Thursday, April 9 | 12:15–1:45 p.m. | Room 208

    Translating Innovation into Real-World Wound Care

    Speakers: Dylan Alston, MD; Trent Brookshier, DPM; Thomas Serena, MD, FACS, FACHM; Peter Moyer, DPM

    Oral Abstracts (G4Derm® Plus by Gel4Med):

    Friday, April 10 | 10:30–11:30 a.m. | Session K2

    Innovative Peptide-Based Technology Provides Antibacterial Protection, Facilitating Rapid and Sustained Closure of Surgical Incisions

    Friday, April 10 | 10:30–11:30 a.m. | Session K3

    Peptide-Based Biomimetic Matrix Eliminates Multidrug-Resistant Pseudomonas in Complex Wounds



    Accepted Clinical & Scientific Poster Presentations:

    1. Dehydrated Human Umbilical Cord Modulates the Effects of TGFβ-Mediated Fibrosis in Support of Wound Management

    2. Lyophilized Human Amnion Chorion Membrane Allografts Modify Inflammatory Monocyte-derived Macrophage's Phenotype in vitro
    3. Refractory Neuropathic Foot Wounds in Medically Complex Patients: Achieving Durable Closure and Function
    4. Bovine-Derived Collagen Matrix as an Adjunct for Post-Amputation Diabetic Foot Wound Dehiscence: A Two-Case Review
    5. Management of a High-Tension Scalp Vertex Defect Using Lyophilized Human Amnion Chorion Membrane Following Mohs Micrographic Surgery: A Case Report
    6. Post-Acute Care of Stalled Pressure Injuries with Placental Allografts
    7. The Novel Use of Dual Layer Chorion Membrane in a Diabetic Polymorbid Patient: A Case Report

    G4Derm® Plus by Gel4Med

    1. Decreasing Bacterial Burden in Infected Wounds using a 3D Biomimetic Matrix
    2. Using a Biomimetic Matrix in Treatment-Resistant Wounds with Autoimmune Etiologies
    3. Peptide Biomimetic Matrix Rescues High-Risk Diabetic Foot Ulcers from Amputation
    4. Safety and Efficacy of a Peptide Biomimetic Matrix in Refractory Lower Extremity Wounds
    5. Peptide Biomimetic Matrix shows Rapid Regranulation of Complex, Deep Wounds requiring Surgical Intervention
    6. Peptide Biomimetic Matrix Revitalizes Chronic Wounds via Tissue Regrowth and Revascularization: Monitoring Progress with Multispectral NIRS Imaging

    DLS 2026

    April 8–11 | Washington, D.C.

    As a Platinum Sponsor of the Diabetic Limb Salvage Conference, MIMEDX will engage with multidisciplinary care teams focused on improving outcomes for patients at risk of amputation. The conference emphasizes collaborative approaches to limb preservation, equipping healthcare professionals with practical strategies and clinical insights.

    Lunch Symposium III:

    Thursday, April 9 | 12:30–1:30 p.m.

    Keys to a Limb Preservation Program & Optimized Wound Bed – Foundations for Better Healing

    Speakers: Matthew J. Murphy, MD, PhD, FRCSC; Karen Bauer, DNP, CNP-FNP, CWS, FAAWC, MAPWCA

    About MIMEDX

    MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company's vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

    Contact:

    Matt Notarianni

    Investor Relations

    470-304-7291

    [email protected]



    Primary Logo

    Get the next $MDXG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDXG

    DatePrice TargetRatingAnalyst
    2/23/2026$10.00Mkt Outperform
    Citizens
    7/2/2024$11.00Overweight
    Cantor Fitzgerald
    3/7/2024$12.00Buy
    Lake Street
    10/27/2023$12.00Buy
    Craig Hallum
    10/13/2022$7.00Buy
    Mizuho
    9/14/2021$20.00 → $8.50Buy
    HC Wainwright & Co.
    7/26/2021$23.00Outperform
    Northland Capital
    More analyst ratings

    $MDXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Capper Joseph H bought $1,268,000 worth of shares (200,000 units at $6.34), increasing direct ownership by 61% to 529,530 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    5/5/25 10:06:51 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Doug Rice bought $35,786 worth of shares (5,000 units at $7.16), increasing direct ownership by 5% to 102,200 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    11/22/23 5:01:18 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel and CAO Hulse William Frank Iv covered exercise/tax liability with 20,245 shares, decreasing direct ownership by 4% to 543,195 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    3/17/26 6:32:28 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Maersk-Moller Kimberly covered exercise/tax liability with 6,762 shares, decreasing direct ownership by 2% to 329,450 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    3/17/26 6:31:14 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Maersk-Moller Kimberly exercised 42,845 shares at a strike of $4.50 and covered exercise/tax liability with 21,270 shares, increasing direct ownership by 7% to 336,212 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    3/12/26 5:37:04 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MIMEDX to Sponsor Leading Advanced Wound Care Conferences

    Multispecialty Focus with Industry Leadership Aimed at Improving Patient Outcomes Company Will Feature Recent Additions to Its Advanced Wound Care Portfolio MARIETTA, Ga., April 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced its participation in two leading wound care conferences: the Symposium on Advanced Wound Care ("SAWC") Spring 2026 and MedStar Georgetown University Hospital's Diabetic Limb Salvage ("DLS") Conference. Through scientific presentations, clinician education, and exhibit presence, MIMEDX will highlight its growing body of clinical evidence and expanding portfolio of solutions designed to support clinicians in m

    4/2/26 9:15:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces Launch of CHORIOFIX™

    MARIETTA, Ga., March 23, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the commercial launch of CHORIOFIX™, the latest advanced wound care innovation in its product portfolio of placental allografts. "CHORIOFIX is an organically developed product, created based on our deep understanding of the scientific and clinical attributes of the chorion layer," stated Michelle Massee, MIMEDX VP, Research & Development. "It consists of two chorion layers with an intact intermediate layer, making it our thickest product to date. The allograft's structure enhances handling, particularly during positioning and suturing, while its uniform, dual-side

    3/23/26 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX® Thyroid Shields

    MARIETTA, Ga., March 05, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the commercial launch of AMNIOFIX Thyroid Shields, a product line extension of the Company's AMNIOFIX dehydrated human amnion/chorion membrane (DHACM) allografts. AMNIOFIX Thyroid Shields are allografts designed and intended for use in endocrine surgery. Following a thyroidectomy, the sheets—provided in preconfigured sizes—are applied to the exposed Recurrent Laryngeal Nerve (RLN) and parathyroid glands to provide a protective barrier and thereby support the healing cascade. The product is designed to prevent the need for intraoperative modification, saving valu

    3/5/26 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    SEC Filings

    View All

    MiMedx Group Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MIMEDX GROUP, INC. (0001376339) (Filer)

    2/25/26 4:02:17 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by MiMedx Group Inc

    10-K - MIMEDX GROUP, INC. (0001376339) (Filer)

    2/25/26 4:01:04 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by MiMedx Group Inc

    SCHEDULE 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

    2/13/26 1:00:16 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citizens initiated coverage on MiMedx Group with a new price target

    Citizens initiated coverage of MiMedx Group with a rating of Mkt Outperform and set a new price target of $10.00

    2/23/26 8:37:40 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on MiMedx Group with a new price target

    Cantor Fitzgerald initiated coverage of MiMedx Group with a rating of Overweight and set a new price target of $11.00

    7/2/24 7:38:13 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on MiMedx Group with a new price target

    Lake Street initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00

    3/7/24 8:26:30 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Leadership Updates

    Live Leadership Updates

    View All

    Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

    Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a

    7/17/24 8:00:00 AM ET
    $MDXG
    $SAVA
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer

    MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company's Senior Vice President, Sales since August 2020. "I am pleased to announce this well-deserved promotion of Kim to Chief Commercial Officer for MIMEDX," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "Under Kim's leadership as SVP of Sales for the past four years, the MIMEDX commercial organization has navigated significant change and has been transformed into the high-performing team we have today. As we continue to work our way through a period of swe

    6/26/24 4:01:00 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces Appointment of Two New Independent Directors

    MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors unanimously agreed to expand its size to eleven directors. M. Kathleen Behrens, Chair of the Board at MIMEDX, stated, "On behalf of the entire Board of Directors, we are honored to welcome these a

    3/4/24 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc

    SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

    11/12/24 4:04:33 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by MiMedx Group Inc

    SC 13G - MIMEDX GROUP, INC. (0001376339) (Subject)

    11/7/24 10:25:58 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc

    SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

    11/4/24 1:30:50 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Financials

    Live finance-specific insights

    View All

    MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results

    Net Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $15 million and $0.10, Respectively Fourth Quarter Adjusted EBITDA1 was $29 Million, or 25% of Net Sales Company Estimates 2026 Net Sales in a Range of $340-360 Million Announces $100 Million Share Repurchase Program Authorization Management to Host Conference Call Today, February 25, 2026, at 4:30 PM ET MARIETTA, Ga., Feb. 25, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the fourth quarter and full year 2025. Joseph H. Capper, MIMEDX Chief Executive

    2/25/26 4:01:00 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25

    MARIETTA, Ga., Feb. 17, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2025 after the market close on Wednesday, February 25, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13758446 A replay of the webcast will be available for approximately 30 days on

    2/17/26 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces Record Revenue for Third Quarter 2025

    Second Consecutive Quarter of Highest Quarterly Net Sales in MIMEDX History  Third Quarter Net Sales of $114 million Grew 35% Year-Over-Year Third Quarter GAAP Net Income and Diluted Earnings Per Share were $17 Million and $0.11, Respectively Third Quarter Adjusted EBITDA was $35 Million, or 31% of Net Sales Raises 2025 Net Sales Growth and Adjusted EBITDA Expectations Management to Host Conference Call Today, October 29, 2025, at 4:30 PM ET MARIETTA, Ga., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the third quarter 2025. Joseph H. Capper, MIMEDX Chief Executive Officer, comment

    10/29/25 4:01:00 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care